pregnancy-specific beta-1-glycoprotein 7

a pregnancy-associated protein; expressed in human fetal liver; belongs to the carcinoembryonic antigen (CEA) gene family of the immunoglobulin superfamily; amino acid sequence given in first source

Also Known As:

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bergman, Lina: 1 article (01/2022)
2.	Cannon, Ping: 1 article (01/2022)
3.	Cluver, Catherine: 1 article (01/2022)
4.	Hannan, Natalie J: 1 article (01/2022)
5.	Hastie, Roxanne: 1 article (01/2022)
6.	Kaitu'u-Lino, Tu'uhevaha J: 1 article (01/2022)
7.	Kandel, Manju: 1 article (01/2022)
8.	Keenan, Emerson: 1 article (01/2022)
9.	MacDonald, Teresa M: 1 article (01/2022)
10.	Myers, Jenny: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "PSG7 was remarkably correlated with clinicopathological parameters (pathologic stage, T stage, and N stage) of PTC patients, and PSG7 expression was elevated in tumor samples from both TCGA and the Gene Expression Omnibus and was strongly associated with progressive stage and poor prognosis. " 01/01/2022 - "PSG7 indicates that age at diagnosis is associated with papillary thyroid carcinoma: A study based on the cancer genome atlas data." 01/01/2020 - "Specifically, CTD-2218G20.2 was predicted to interact with PSG4, PSG5, and PSG7, which could also interact with cancer-related proteins, including KISS1, TIMP2, MMP11, IGFBP1, EGFR, and CDKN1C, suggesting that CTD-2218G20.2 might participate in the cancer progression via these cancer-related proteins. "
2.	Papillary Thyroid Cancer 01/01/2022 - "PSG7 indicates that age at diagnosis is associated with papillary thyroid carcinoma: A study based on the cancer genome atlas data."
3.	Pre-Eclampsia (Preeclampsia) 01/01/2022 - "To examine whether PSG7 and PSG9 are associated with increasing disease severity, we measured them in a cohort from South Africa stratified for this outcome, the PROVE (Preeclampsia Obstetric Adverse Events) cohort (n=72). " 01/01/2022 - "These changes were validated in the plasma and placentas of patients with established preeclampsia who delivered at <34 weeks gestation (PSG7, P=0.0008; PSG9, P<0.0001). " 01/01/2022 - "Methods and Results At 36 weeks gestation preceding term preeclampsia diagnosis, PSG7 and PSG9 (in Australian cohorts of n=918 and n=979, respectively) were significantly increased before the onset of term preeclampsia (PSG7, P=0.013; PSG9, P=0.0011). " 01/01/2022 - "Conclusions Circulating PSG7 and PSG9 are increased before preeclampsia onset and among those with established disease with their production and release potentially driven by placental inflammation." 01/01/2022 - "In samples collected at 28 to 32 weeks from those with preexisting cardiovascular disease and at high risk of preeclampsia (Manchester Antenatal Vascular Service, UK cohort, n=235), both PSG7 and PSG9 were also significantly increased preceding preeclampsia onset (PSG7, P<0.0001; PSG9, P=0.0003) relative to controls. "
4.	Inflammation (Inflammations) 01/01/2022 - "Conclusions Circulating PSG7 and PSG9 are increased before preeclampsia onset and among those with established disease with their production and release potentially driven by placental inflammation."
5.	Eclampsia 01/01/2022 - "PSG7 (P=0.0027) and PSG9 (P=0.0028) were elevated among patients who were preeclamptic with severe features (PROVE cohort), but not significantly changed in those without severe features or with eclampsia. "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Proteins (Proteins, Gene)
3.	Glycoproteins (Glycoprotein)